Gapping up
In reaction to earnings/guidance:
- MEDP +26.1%, AAN +12.2%, XM +9.6%, CLS +7.4%, CALX +7.3%, LOGI +6.9%, ARI +6%, SHW +5.7%, UBS +5.5%, GM +5.2%, GE +3.9%, ADTN +3.4%, UPS +3.3%, HUBB +3%, BNR +2.9%, SAP +2.8%, KO +2.8%, SSB +2.4%, BIIB +2.3%, AGNC +2%, ADM +1.9%, HAL +1.6%, HLX +1.5%, HXL +1.4%, ARCC +1.2%, NVS +0.9%, KMB +0.6%
Other news:
- WEBR +24.5% (BDT Capital offers to acquire WEBR at $6.25/share in cash)
- GRTS +5.3% (Phase 1 results from its ongoing CORAL-BOOST and CORAL-CEPI trials evaluating its self-amplifying mRNA vaccine candidates against SARS-CoV-2; also announces private placement of $45.0 mln)
- EEFT +5% (amends and extends its unsecured revolving credit facility)
- PRIM +3.9% (awarded $400 mln worth of projects)
- COOK +2.3% (trading higher in sympathy with WEBR)
- GHM +2.2% (achieves record $92 mln in orders in Q2)
- BCML +1.6% (authorizes up to 5% in repurchases)
- MIST +1.6% (Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the American Heart Association Scientific Sessions 2022)
- LAUR +1.4% (approves special cash dividend)
- AVDL +1.1% (presents new data)
Analyst comments:
- HIBB +5.3% (upgraded to Buy from Neutral at BofA Securities)
- ASB +1.2% (upgraded to Neutral from Underperform at BofA Securities)
- NFLX +0.8% (upgraded to Outperform from Neutral at Daiwa Securities)
